KRAS and colorectal carcinoma: For the MSKCC CRC cohort, there was no difference in OS between patients with TP53, KRAS, PIK3CA, SMAD4, and NRAS mutations and wild type (p = 0.42, 0.39, 0.4, 0.26, and 0.16, respectively; Figure A10).